Alan K. Hauser, Ph.D. Telephone: 847-721-1200

Deerfield, IL 60015 E-Mail: ahauser@usa.net

SUMMARY OF QUALIFICATIONS

Accomplished life sciences commercialization leader having translated proprietary

innovations from the bench to the marketplace via new venture creation and licensing

Strong technical/IP assessment capabilities; formidable product roadmapping acumen

Certified Licensing ProfessionalTM

; demonstrated ability to value and drive deals

For 15 years, have helped build businesses based on disruptive biotechnologies

that are transforming the way research and medicine is practiced, including:

– Commercialized FDA-cleared, microarray-enabled DNA diagnostics products

– Developed and managed a broad microfluidics patent portfolio for a

venture-backed bioscience company that resulted in its $189 million IPO

EXPERIENCE

Northwestern University, Evanston and Chicago, IL 2008 2011

Executive Director of Technology Licensing and Business Development

NU Innovation and New Ventures Office (INVO), formerly known as NU TTP 2010 2011

Managed Technology Licensing Team (6 professionals and 40 interns) responsible for:

Evaluating approximately 200 invention disclosures per year

Overseeing 30 executed and 20 pending license agreements this year

Licensing revenue in excess of $150 million per year for the past 3 years

Director of Business Development, NU Technology Transfer Program (TTP) 2008 2010

Bridged the gap between NU research and its practical use for public benefit

Marketed in excess of 150 technologies/patent portfolios

Led structuring and negotiating of 20 license/option agreements

Built/nurtured culture of innovation, including 40 NUCo startups, which

raised $199 million in venture/corporate investment this year (2010-2011)

Bio-Com International, Deerfield, IL 2011 present

Managing Director of biosciences commercial development consultancy committed to 2004 2008

assisting companies create value by enhancing and sustaining their competitive advantage

Developed Bio-Com’s Bio-Biz Builder (B4U)

SM strategy, IP appraisal, technology /

product roadmapping, and financial frameworks to forecast varying market scenarios

Helped fuel clients’ innovation growth engine that will enable future profitability

Developed compelling strategic plans for high-impact market expansion

opportunities based on forward-looking intelligence and valuation analytics

Exploited commercial potential of emerging bio-detection technology more

broadly so when realized will quadruple public company’s annual gross profit

Assessed competitive IP landscape and marketability of emerging biotechnologies

Clinical Micro Sensors, a Motorola Company sold to Osmetech plc, GenMark Dx 2002 2004

Sr. Business Development Manager of biochip business unit based in Pasadena, CA

Secured commercial IP rights for eSensorTM molecular diagnostics platform

Led strategic roadmapping to assess ‘build-vs.-buy’ opportunities by linking

technology/IP to product functionality driven by customer’s value proposition

and demand as determined by my competitive market intelligence and research

Invited speaker on bio-nano convergence commercialization in U.S., Japan, Israel, China

Negotiated royalty reductions up to 95% enabling multi-million-dollar cost savings

by employing profitability analysis and my weighted-contribution royalty structure

Alan K. Hauser, Ph.D.

Motorola Life Sciences sold to Amersham Biosciences, GE Healthcare, Surmodics 1999 2002

Business and Strategy Development Sr. Manager of biotools business unit in Northbrook, IL

Identified and assessed new opportunities and executed licenses in support of

launch of CodeLinkTM

gene expression and SNP genotyping microarray products

Created, developed and implemented market-development initiative for

Massively-Parallel, Multi-Plexed Genomics (MPGx) commercial offering

Received Motorola BRAVO! Leadership Award for championing MPGx program

Directed commercial aspects of MLS' exploratory proteomics initiative

Conducted biotech-business and IP due-diligence for Motorola Ventures

ACLARA BioSciences, sold to Monogram Biosciences, A LabCorp Company 1997 1999

Intellectual Property and Licensing Director of Bay Area lab-on-a-chip venture

Managed and built broad IP portfolio from ~10 U.S. patents and applications to more

than 130 pending and issued U.S. patents plus hundreds worldwide enabling $189 M IPO

Co-invented microfluidic methods for drug screening/genetic analyses that resulted

in 4 U.S. patents and more than a dozen pending applications/foreign equivalents

Developed and employed freedom-to-operate and strategic market landscaping tools for

visualizing and analyzing competitive technology-IP (TIP) space and new product offerings

Prepared and presented TIP marketing materials that led to 3 major corporate partnerships

Pangene Corporation, sold to NaPro BioTherapeutics, Tapestry Pharmaceuticals 1995 1996

Business Development Director of Bay Area biotechnology tools and services venture

Consummated licenses to DNA recombination methods for transgenesis, therapy and diagnostics

Refocused business plan and spearheaded marketing efforts leading to 1st corporate collaboration

SRI International (formerly Stanford Research Institute), Menlo Park, CA 1992 1995

Technology Assessment and Marketing Consultant, at Contract Research Organization

Evaluated commercial potential of emerging biotechnologies for Business Intelligence Center

Conducted and managed client-funded feasibility investigations in Science & Technology Group

EDUCATION

Professional business training and development

Executive Program in Business Admin., Kellogg Management Institute, Northwestern University

Executive Finance Programs: Valuation and Corporate Venture Capital, Harvard Business School

MBA Courses: Technology Strategy, Corporate Finance, Private Equity and

Entrepreneurial Finance, Booth School of Business, University of Chicago

Postdoctoral Fellow, Hawaii Biosensor Lab, Dept. of Chemistry, University of Hawaii, Honolulu

Co-wrote successful NIH grant proposal that resulted in funding to develop miniaturized

molecular-recognition sensors and assays for pharmaceutical drug discovery and development

Postdoctoral Fellow, Dept. of Chemical Engineering and Chemistry, University of Texas, Austin

Optimized microfabricated biosensors, which became basis for Dx venture acquired for $1.2 billion

Ph.D. Chemical Engineering, College of Chemistry, University of California, Berkeley

Developed and characterized analytical detection method having diagnostics applications

Page 2 of 2